CAREstream America announces an exclusive distribution partnership to bring Celltermi HS and NX Plus, an advanced probiotic-derived microbiome technology, to the US market. Celltermi...
LIVONIA, Mich., June 8, 2026 /PRNewswire/ -- Cabinetworks Group, the country's largest privately owned cabinet manufacturer, recently announced it has appointed Danielle Mikesell as...
NINGBO, China, June 8, 2026 /PRNewswire/ -- Robotics, semiconductor equipment, and intelligent automation systems are evolving at an accelerating pace, placing OEM manufacturers under...
HANGZHOU, China, June 8, 2026 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190; "Zylox-Tonbridge" or the "Company"), a Hong Kong-listed medical technology company...
EISENERZ, Austria, June 8, 2026 /PRNewswire/ -- Segway Powersports recently participated in the 2026 Red Bull Erzbergrodeo in Erzberg, Austria, bringing its AT10 999cc...
EISENERZ, Austria, June 8, 2026 /CNW/ -- Segway Powersports recently participated in the 2026 Red Bull Erzbergrodeo in Erzberg, Austria, bringing its AT10 999cc...
REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.
VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...
Driven by intensifying food safety requirements with the increased stringency of regulatory guidelines, a substantial and growing incidence of food fraud across global supply...
Driven by intensifying food safety requirements with the increased stringency of regulatory guidelines, a substantial and growing incidence of food fraud across global supply...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.
Clinical Study Showed Up to 48% Natural Killer Cell Increase with probiotic strain LP281VANCOUVER, BC, June 5, 2026 /PRNewswire/ -- Synbio Tech Inc. (SynbioTech),...
Arbitrum-based prediction market protocol prepares for global expansion with AI-powered market resolution, expanded liquidity infrastructure, and upcoming Version 2 release
Exotic Pets Steal the Spotlight with Debut Reptilia Carnival and Live Insect Exhibition Featuring Over 50 SpeciesHONG KONG, June 5, 2026 /PRNewswire/ -- Organized...